Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 12,678 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 12,678 shares of Castle Biosciences stock in a transaction on Friday, October 31st. The stock was sold at an average price of $25.04, for a total transaction of $317,457.12. Following the sale, the chief operating officer directly owned 27,569 shares in the company, valued at $690,327.76. This trade represents a 31.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Castle Biosciences Stock Performance

Shares of CSTL opened at $31.63 on Wednesday. The business’s 50 day moving average is $23.45 and its two-hundred day moving average is $20.17. The firm has a market cap of $917.59 million, a price-to-earnings ratio of -70.29 and a beta of 1.12. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $35.84. The company has a quick ratio of 6.69, a current ratio of 6.85 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.32. The company had revenue of $83.04 million during the quarter, compared to the consensus estimate of $71.06 million. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.75%. Castle Biosciences has set its FY 2025 guidance at EPS. Analysts forecast that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CSTL. Farther Finance Advisors LLC boosted its position in Castle Biosciences by 139,100.0% in the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock valued at $32,000 after buying an additional 1,391 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in Castle Biosciences in the third quarter valued at about $35,000. CWM LLC boosted its position in Castle Biosciences by 80.6% in the third quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after buying an additional 853 shares in the last quarter. Harbour Investments Inc. bought a new position in Castle Biosciences in the 1st quarter valued at $50,000. Finally, Jones Financial Companies Lllp raised its position in Castle Biosciences by 10,592.0% in the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after purchasing an additional 2,648 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CSTL. BTIG Research reaffirmed a “buy” rating on shares of Castle Biosciences in a research note on Tuesday. Robert W. Baird raised their price target on shares of Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Castle Biosciences in a report on Thursday, October 30th. Wall Street Zen upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 10th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $37.00 price target on shares of Castle Biosciences in a research report on Tuesday, September 9th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $37.33.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.